Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Madrigal Pharmaceuticals (MDGL) over the last 5 years, with Q3 2025 value amounting to $7.5 million.

  • Madrigal Pharmaceuticals' Interest Expenses rose 10252.79% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 1563.0%. This contributed to the annual value of $14.7 million for FY2024, which is 1541.06% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Interest Expenses of $7.5 million as of Q3 2025, which was up 10252.79% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Interest Expenses ranged from a high of $7.5 million in Q3 2025 and a low of $780000.0 during Q2 2022
  • Its 4-year average for Interest Expenses is $3.2 million, with a median of $3.4 million in 2024.
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 27192.31% in 2023, then crashed by 1409.59% in 2025.
  • Over the past 4 years, Madrigal Pharmaceuticals' Interest Expenses (Quarter) stood at $1.7 million in 2022, then soared by 136.09% to $4.0 million in 2023, then dropped by 11.89% to $3.5 million in 2024, then surged by 112.95% to $7.5 million in 2025.
  • Its Interest Expenses was $7.5 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.3 million in Q1 2025.